Societe Generale’s Edwards Lifesciences EW Stock Holding History

Societe Generale’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$904K	Buy	+27,183	New	+$930K	0.01%	1369

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Societe Generale's EW Position: Q2 2016 in Review

Societe Generale opened a new position in Edwards Lifesciences (EW) in Q2 2016: 27,183 shares worth $904K. The stake represents 0.01% of the portfolio and ranks #1369 among its holdings.

692 funds tracked by Wall St. Rank hold EW as of Q2 2016.

Societe Generale held 27,183 shares of Edwards Lifesciences worth $904K as of Q2 2016.
Edwards Lifesciences was a new Societe Generale position in Q2 2016.
Edwards Lifesciences made up 0.01% of Societe Generale's portfolio in Q2 2016, its #1369 holding.
692 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.